Accordingly, this study has provided a novel mechanism for a selective degeneration of cholinergic neurons in AD, possibly by a proteolytic process of NRADD in D28K+ neurons (Fig. S4) and hence warrants a promising molecular target for AD therapy. This evidence concerns the gene CALB1 and Alzheimer disease.